TITLE

Everolimus improved PFS in neuroendocrine tumors

AUTHOR(S)
Harris, Jason
PUB. DATE
February 2011
SOURCE
Hem/Onc Today;2/25/2011, Vol. 12 Issue 4, p18
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article reports on the results of the RADIANT-2 phase 3 trial which found that everolimus can enhance the medical condition of patients with neuroendocrine tumors.
ACCESSION #
62393622

 

Related Articles

  • Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Grande, E.; Capdevila, J.; Castellano, D.; Teulé, A.; Durán, I.; Fuster, J.; Sevilla, I.; Escudero, P.; Sastre, J.; García-Donas, J.; Casanovas, O.; Earl, J.; Ortega, L.; Apellaniz-Ruiz, M.; Rodriguez-Antona, C.; Alonso-Gordoa, T.; Díez, J. J.; Carrato, A.; García-Carbonero, R. // Annals of Oncology;Sep2015, Vol. 26 Issue 9, p1987 

    Background: The management of advanced neuroendocrine tumors (NETs) has recently changed. We assessed the activity of pazopanib after failure of other systemic treatments in advanced NETs. Methods: This was a multicenter, open-label, phase II study evaluating pazopanib as a single agent in...

  • A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies. Deeken, John; Slack, Rebecca; Weiss, Glen; Ramanathan, Ramesh; Pishvaian, Michael; Hwang, Jimmy; Lewandowski, Karen; Subramaniam, Deepa; He, Aiwu; Cotarla, Ion; Rahman, Aquilur; Marshall, John // Cancer Chemotherapy & Pharmacology;Mar2013, Vol. 71 Issue 3, p627 

    Background: Docetaxel is a taxane anticancer drug used in a wide variety of solid tumors. Liposomes are versatile drug carriers that may increase drug solubility, serve as sustained release systems, provide protection from drug degradation and toxicities, and help overcome multidrug resistance....

  • Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study Wolin, Edward; Hu, Ke; Hughes, Gareth; Bouillaud, Emmanuel; Giannone, Vanessa; Resendiz, Karina // Cancer Chemotherapy & Pharmacology;Aug2013, Vol. 72 Issue 2, p387 

    Purpose: Pasireotide (SOM230), a novel multireceptor ligand somatostatin analog (SSA), binds with high affinity to four of the five somatostatin receptor subtypes (sst). This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics profiles of pasireotide long-acting...

  • Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors. Chan, Jennifer; Mayer, Robert; Jackson, Nadine; Malinowski, Paige; Regan, Eileen; Kulke, Matthew // Cancer Chemotherapy & Pharmacology;May2013, Vol. 71 Issue 5, p1241 

    Purpose: Sorafenib and everolimus are both active against neuroendocrine tumors (NET). Because of potential synergy between VEGF pathway and mTOR inhibitors, we performed a phase I study to evaluate the safety and feasibility of combining sorafenib and everolimus in patients with advanced NET....

  • Rare malignant neuroendocrine transformation of a presacral teratoma in patient with currarino syndrome. Pendlimari, Rajesh; Leonard, Daniel; Dozois, Eric J. // International Journal of Colorectal Disease;Nov2010, Vol. 25 Issue 11, p1383 

    A letter to the editor is presented regarding a 22-year-old female with currarino syndrome (CS) whose presacral teratoma became a malignant neuroendocrine tumor.

  • Sunitinib.  // Reactions Weekly;8/10/2013, Issue 1465, p34 

    An abstract of the article "Sunitinib-induced hyperammonaemia in a patient with pancreatic neuroendocrine tumour," by Y. F. Shea and colleagues is presented.

  • Rhenium-188-etidronic acid.  // Reactions Weekly;Apr2015, Vol. 1548 Issue 1, p223 

    The article presents case studies of patients with peptide receptor radionuclide therapy-refractory bone metastases of gastroenteropancreatic tumours, who developed relevant haematotoxicity while on treatment with rhenium-188-etidronic acid.

  • New Medical Strategies for Midgut Carcinoids. Nilsson, Ola; Arvidsson, Yvonne; Johanson, Viktor; Forssell-Aronsson, Eva; Ahlman, H�kan // Anti-Cancer Agents in Medicinal Chemistry;2010, Vol. 10 Issue 3, p250 

    Patients with well-differentiated neuroendocrine tumours of the gastrointestinal tract often present with metastases and hormonal symptoms. These patients can be palliated by interventional tumour reduction and medical treatment with somatostatin analogues; no effective chemotherapy is...

  • Skeletal Muscle Metastases in a Patient With Neuroendocrine Tumor. Santos-Cabalona, Wilhelmina delos; Kozyreva, Olga N.; Davidoff, Ashley; Wolfe, Gail; Hackford, Alan // World Journal of Oncology;2013, Vol. 4 Issue 2, p114 

    Carcinoid tumors are rare but diverse group of malignancies that arise from neuroendocrine cells. Skeletal muscle metastasis is exceedingly rare and is associated with a poor prognosis. We report a case of carcinoid tumor of the ileocecal with skeletal muscle metastasis. We also review available...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics